# Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor

> **NCT00483093** · PHASE1 · COMPLETED · sponsor: **AGC Biologics S.p.A.** · enrollment: 22 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** NGR-hTNF
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00483093
- **Lead sponsor:** AGC Biologics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-06
- **Final completion:** 2013-04
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00483093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00483093, "Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00483093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*